Publications by authors named "Dinko Vitezic"

Claim this Profile
M
Methodological considerations on paracetamol pharmacokinetics in spinal muscular atrophy: A response to Zhao et al.
Elvira Meni Maria Gkrinia, Iva Kristić, Andrej Belančić, Dinko Vitezić, Hesham S Al-Sallami

Br J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of nusinersen-risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković

Br J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-career pre-congress meetings: investing in talent, transforming the future of clinical pharmacology.
Andrej Belančić, Kaisa Litonius, Noora Kulla, Robert Likić, Slobodan Janković

Eur J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the editor: Expanding DPYD genotyping panels beyond current guidelines-real-world evidence and clinical-economic thoughts on inclusion of additional variants.
Silvestar Mežnarić, Jelena Rajič Bumber, Jasenka Mršić-Pelčić, Dinko Vitezić, Andrej Belančić

Br J Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of cystic fibrosis transmembrane conductance regulator modulators: A systematic review of economic evaluations.
Andrea Katrin Faour, Andrej Belančić, Ida Štimac, Elvira Meni Maria Gkrinia, Judite Goncalves

Br J Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of therapies approved for spinal muscular atrophy: A narrative review of current evidence.
Eda Kübra Sel, Elvira Meni Maria Gkrinia, Rossana Roncato, Dinko Vitezić, Slobodan Janković

J Int Med Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in publicly and privately prescribed anxiolytics in Croatia: do we need a new regulatory framework.
Marta Kučan Štiglić, Tea Strbad, Andrej Belančić, Jasenka Mršić Pelčić, Dinko Vitezić

Int J Pharm Pract· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor: The Pharmacological Responsibility Chain - Mapping Competence Toward Responsible Prescribing.
Almir Fajkić, Andrej Belančić, Dinko Vitezić

Hosp Pharm· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverging Safety Signals: A Trend Analysis of Suspected Adverse Drug Reactions Reporting for Spinal Muscular Atrophy Therapies in the European Union.
Andrej Belančić, Petar Mas, Ivana Stević, Dinko Vitezić, Slobodan Janković

Neurol Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in 25 years of antihypertensive agent utilization in Croatia - an alert for scientific community and healthcare providers.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić

Br J Clin Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescribe less, ask more: the patient-centred pharmacology we need.
Andrej Belančić, Almir Fajkić, Dinko Vitezić

Eur J Hosp Pharm· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transforming Spinal Muscular Atrophy: From Pivotal Trials to Real-World Evidence and Future Therapeutic Frontiers in Types 1 and 2.
Andrej Belančić, Patrick Castillo Eustaquio, Elvira Meni Maria Gkrinia, Valentino Rački, Kristina Pilipović

Biomedicines· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of Child-Appropriate Medicines: Use of Pediatric Use Marketing Authorisation (PUMA) Products in Croatia.
Andrej Belančić, Marta Kučan Štiglić, Arnes Rešić, Almir Fajkić, Dinko Vitezić

J Clin Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the Impact of Different Antiarrhythmic Classes on Clinical Outcomes Following Atrial Fibrillation Catheter Ablation.
Andrej Belančić, Yusuf Ziya Sener, Metin Oksul, Cansu Ozturk, Serdar Soner

Pharmaceuticals (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prenatal Management of Spinal Muscular Atrophy in the Era of Genetic Screening and Emerging Opportunities in In Utero Therapy.
Silvestar Mežnarić, Andrej Belančić, Valentino Rački, Dinko Vitezić, Jasenka Mršić-Pelčić

Biomedicines· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in Europe.
Gloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, Enrico Costa, Dinah M Duarte, Dinko Vitezic

Mol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in Lipid-Lowering Agent Consumption in Croatia: A 25-Year Observational Study.
Andrej Belančić, Marta Kučan Štiglić, Luka Prgomet, Ivan Pećin, Željko Reiner

Pharmacol Res Perspect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs of Treating Onasemnogene Abeparvovec-Xioi-Induced Liver Injury.
Andrej Belančić, Branislava Raičević, Ivana Stević, Dinko Vitezić, Slobodan M Janković

Pharmacol Res Perspect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching disease-modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić

Br J Clin Pharmacol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance.
Andrej Belančić, Petar Mas, Lara Miletić, Barbara Kovačić Bytyqi, Dinko Vitezić

J Clin Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases.
Andrej Belančić, Elvira Meni Maria Gkrinia, Robert Likić, Dinko Vitezić

Br J Clin Pharmacol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glial Cells in Spinal Muscular Atrophy: Speculations on Non-Cell-Autonomous Mechanisms and Therapeutic Implications.
Andrej Belančić, Tamara Janković, Elvira Meni Maria Gkrinia, Iva Kristić, Jelena Rajič Bumber

Neurol Int· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review of economic evaluations of orphan medicines for the management of spinal muscular atrophy.
Andrej Belančić, Andrea Katrin Faour, Elvira Meni Maria Gkrinia, Dinko Vitezić

Br J Clin Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury.
Anja Harej Hrkać, Kristina Pilipović, Andrej Belančić, Lea Juretić, Dinko Vitezić

Pharmaceuticals (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?
Andrej Belančić, Andrea Katrin Faour, Elvira Meni Maria Gkrinia, Dinko Vitezić

Croat Med J· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis